{
    "clinical_study": {
        "@rank": "52022", 
        "arm_group": [
            {
                "arm_group_label": "Part I - MK-8521 64/120 \u03bcg/day", 
                "arm_group_type": "Experimental", 
                "description": "Participants will receive once daily subcutaneous MK-8521 (starting dose 64 \u03bcg/day Days 1 to 7 escalated to 120 \u03bcg/day for Days 8 to 14)."
            }, 
            {
                "arm_group_label": "Part I - MK-8521 34/72 \u03bcg/day", 
                "arm_group_type": "Experimental", 
                "description": "Participants will receive once daily subcutaneous MK-8521(starting dose 34 \u03bcg/day Days 1 to 7 escalated to 72 \u03bcg/day for Days 8 to 14)."
            }, 
            {
                "arm_group_label": "Part I - Liraglutide 0.6/1.2/1.8 mg/day", 
                "arm_group_type": "Active Comparator", 
                "description": "Participants will receive once daily subcutaneous liraglutide (starting dose 0.6 mg on Day 1 and 2, escalated to 1.2 mg on Days 3 to 7, escalated to 1.8 mg for Days 8 to 14)."
            }, 
            {
                "arm_group_label": "Part I - Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Participants receive a dose of placebo that will match the administration volume of MK-8521."
            }, 
            {
                "arm_group_label": "Part II - MK-8521 300 ug/day - T2DM Participants", 
                "arm_group_type": "Experimental", 
                "description": "For T2DM participants, MK-8521 titrated to 300 ug/day. Starting at 64 ug and increasing to 120 ug on Day 8 and to 180 ug on Day 15 and increasing to 240 ug on Day 20 and to 300 ug on Day 25. The total number of dosing days will be 29."
            }, 
            {
                "arm_group_label": "Part II - Liraglutide 1.8 mg/day - T2DM Participants", 
                "arm_group_type": "Active Comparator", 
                "description": "Liraglutide titrated to 1.8 mg/day for 29 days. Starting at 0.6 mg and increasing to 1.2 mg on Day 8 and to 1.8 mg on Day 15."
            }, 
            {
                "arm_group_label": "Part II - Placebo - T2DM Participants", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Participants receive a dose of placebo that will match the administration volume of MK-8521 across the 29 days."
            }, 
            {
                "arm_group_label": "Part II - MK-8521 120 ug/day - Non-Diabetic Participants", 
                "arm_group_type": "Experimental", 
                "description": "For non-diabetic overweight/obese participants MK-8521 titrated to 120 ug/day. The total dosing days will be 14 days, starting at 64 ug and increasing to 120 ug on Day 8."
            }
        ], 
        "brief_summary": {
            "textblock": "This study will evaluate the safety, efficacy, and pharmacokinetics of MK-8521 given once\n      daily compared to placebo and another diabetes drug in participants with Type 2 diabetes\n      mellitus (T2DM).\n\n      This study was modified by a protocol amendment to a 2-part trial to further test the safety\n      and tolerability of MK-8521 at higher doses and to compare MK-8521 pharmacokinetics between\n      participants with T2DM and healthy participants.   An additional cohort of T2DM participants\n      and a cohort of non-diabetic obese participants have been added."
        }, 
        "brief_title": "Study of the Safety and Efficacy of MK-8521 Compared to Placebo and a Diabetes Drug in Participants With Type 2 Diabetes Mellitus (MK-8521-003)", 
        "completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Diabetes Mellitus", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male, or female of non-childbearing potential with Type 2 diabetes mellitus (Parts I\n             and II) or non-diabetic (Part II)\n\n          -  Body mass index (BMI) between: 27 >= and <= 40 kg/m^2\n\n          -  A1C (average blood sugar for the past 2 to 3 months) value >= 7.0 and <= 11.0 % (Part\n             I) or >= 6.5 and <= 11.0 % (Part II) at the time of screening (T2DM participants)\n\n          -  A1C value < 5.7 at the time of screening (non-diabetic subjects in Part II only)\n\n          -  On a stable dose of metformin (>=1000 mg total daily dose) for at least 12 weeks at\n             the time of screening (T2DM participants)\n\n        Exclusion Criteria:\n\n          -  Mentally or legally incapacitated\n\n          -  History of clinically significant psychiatric disorder of the last 5 years.\n             Participants with situational depression may be enrolled in the trial at the\n             discretion of the Investigator\n\n          -  History of Type 1 diabetes mellitus or a history of ketoacidosis\n\n          -  History of clinically significant gastrointestinal, hematological, hepatic,\n             immunological, renal, respiratory, genitourinary or major neurological abnormalities\n             or diseases\n\n          -  History of cardiovascular disease or cardiac conduction disorder\n\n          -  History of cancer (malignancy).  Exceptions may include adequately treated\n             non-melanomatous skin carcinoma or carcinoma in situ of the cervix or other\n             malignancies which have been successfully treated >=10 years prior to the\n             pre-screening visit\n\n          -  History of proliferative diabetic retinopathy or maculopathy\n\n          -  Clinically significant diabetic autonomic neuropathy\n\n          -  QTc interval >= 470 msec (for males) or >= 480 msec (for females)\n\n          -  Clinical significant electrocardiogram (ECG) abnormality\n\n          -  Positive for hepatitis B surface antigen, hepatitis C antibodies, or human\n             immunodeficiency virus (HIV)\n\n          -  On a weight loss program and is not weight-stable (weight stable is defined history\n             of <5% change in body weight in the last 3 months\n\n          -  On a weight loss medication or has undergone bariatric surgery\n\n          -  Major surgery, donated or lost 1 unit of blood (approximately 500 mL) within 4 weeks\n             prior to the pretrial (screening) visit\n\n          -  Participated in another investigational trial within 4 weeks prior to the pretrial\n             (screening) visit\n\n          -  History of acute or chronic pancreatitis of any etiology\n\n          -  Mean value for triplicate semi-recumbent systolic blood pressure >160 mm Hg and/or\n             diastolic blood pressure >90 mm Hg (after at least a 10-minute seated rest) and blood\n             pressure is considered unlikely to be below these limits by Day-1 (Randomization)\n             with initiation or adjustment of antihypertensive medication\n\n          -  Event of severe hypoglycemia with seizure or loss of consciousness in the past 12\n             months\n\n          -  Treated with anti-hyperglycemic agents other than metformin within the last 12 weeks\n\n          -  Previous exposure to any glucagon-like peptide-1 (GLP-1) receptor agonist (e.g.\n             Byetta\u2122, Victoza\u2122 or investigational agents)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "84", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01982630", 
            "org_study_id": "8521-003"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Part I - MK-8521 64/120 \u03bcg/day", 
                    "Part I - MK-8521 34/72 \u03bcg/day", 
                    "Part II - MK-8521 300 ug/day - T2DM Participants", 
                    "Part II - MK-8521 120 ug/day - Non-Diabetic Participants"
                ], 
                "intervention_name": "MK-8521", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Part I - Liraglutide 0.6/1.2/1.8 mg/day", 
                    "Part II - Liraglutide 1.8 mg/day - T2DM Participants"
                ], 
                "intervention_name": "Liraglutide", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Part I - Placebo", 
                    "Part II - Placebo - T2DM Participants"
                ], 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 27, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Tempe", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85283"
                    }, 
                    "name": "Call for Information (Investigational Site 0001)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33169"
                    }, 
                    "name": "Call for Information (Investigational Site 0006)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Neptune", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "07753"
                    }, 
                    "name": "Call for Information (Investigational Site 0003)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Knoxville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37920"
                    }, 
                    "name": "Call for Information (Investigational Site 0004)"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "8", 
        "official_title": "A Phase Ib, Multicenter, Placebo and Active- Comparator-Controlled, Randomized, Double-Blind, Clinical Trial to Evaluate the Safety and Efficacy of MK-8521 Compared to Placebo and a Diabetes Drug in Subjects With Type 2 Diabetes Mellitus", 
        "overall_contact": {
            "last_name": "Toll Free Number", 
            "phone": "1-888-577-8839"
        }, 
        "overall_official": {
            "affiliation": "Merck Sharp & Dohme Corp.", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Part I - Number of Participants Experiencing Adverse Events (AEs)", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 42 days"
            }, 
            {
                "measure": "Part I - Number of Participants Discontinuing Study Drug Due to AEs", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 14 days"
            }, 
            {
                "measure": "Part I - Change from Baseline in Time-Weighted Average (TWA) Heart Rate over 24 hours (TWA0-24)", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline and Day 7"
            }, 
            {
                "measure": "Part I - Change from Baseline in TWA0-24", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Day 14"
            }, 
            {
                "measure": "Part I - Area Under the Curve from Hour 0 to Hour 24 (AUC0-24) for MK-8521 Daily Dosing", 
                "safety_issue": "No", 
                "time_frame": "Days 1 and 7 (predose, 1, 2, 4, 6, 8, 10, 12, 16, and 24 hours post-dose); Day 14 (predose,1, 2, 4, 6, 8, 10, 12, 16, and 24 hours post-dose)"
            }, 
            {
                "measure": "Part I - Maximum Concentration (Cmax) for MK-8521 Daily Dosing", 
                "safety_issue": "No", 
                "time_frame": "Days 1 and 7 (predose, 1, 2, 4, 6, 8, 10, 12, 16, and 24 hours post-dose); Day 14 (predose, 1, 2, 4, 6, 8, 10, 12, 16, 24, 72, 96, and 120 hours post-dose)"
            }, 
            {
                "measure": "Part I - Lowest Concentration (Ctrough) for MK-8521 Daily Dosing", 
                "safety_issue": "No", 
                "time_frame": "Predose on Days 2, 4, 6, 7, 9, 11, 13, and 14"
            }, 
            {
                "measure": "Part I - Time to Maximum Concentration (Tmax) for MK-8521 Daily Dosing", 
                "safety_issue": "No", 
                "time_frame": "Days 1 and 7 (predose, 1, 2, 4, 6, 8, 10, 12, 16, and 24 hours post-dose); Day 14 (predose, 1, 2, 4, 6, 8, 10, 12, 16, 24, 72, 96, and 120 hours post-dose)"
            }, 
            {
                "measure": "Part I - Half-life (T1/2) for MK-8521 Daily Dosing", 
                "safety_issue": "No", 
                "time_frame": "Days 1 and 7 (predose, 1, 2, 4, 6, 8, 10, 12, 16, and 24 hours post-dose); Day 14 (predose, 1, 2, 4, 6, 8, 10, 12, 16, 24, 72, 96, and 120 hours post-dose)"
            }, 
            {
                "measure": "Part I - Accumulation Ratio for MK-8521 Daily Dosing", 
                "safety_issue": "No", 
                "time_frame": "Days 1 and 7 (predose, 1, 2, 4, 6, 8, 10, 12, 16, and 24 hours post-dose); Day 14 (predose, 1, 2, 4, 6, 8, 10, 12, 16, 24, 72, 96, and 120 hours post-dose)"
            }, 
            {
                "measure": "Part II - Number of Participants with T2DM Experiencing Adverse Events (AEs)", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 57 days"
            }, 
            {
                "measure": "Part II - Number of Participants with T2DM Discontinuing Study Drug Due to AEs", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 29 days"
            }, 
            {
                "measure": "Part II - Change from Baseline in TWA0-24 at Day 7", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline and Day 7"
            }, 
            {
                "measure": "Part II - Change from Baseline in TWA0-24 at Day 14", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline and Day 14"
            }, 
            {
                "measure": "Part II - Change from Baseline in TWA0-24 at Day 19", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline and Day 19"
            }, 
            {
                "measure": "Part II - Change from Baseline in TWA0-24 at Day 24", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline and Day 24"
            }, 
            {
                "measure": "Part II - Change from Baseline in TWA0-24 at Day 29", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline and Day 29"
            }, 
            {
                "measure": "Part II - Change from Baseline in Peak Heart Rate at Day 7", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Day 7"
            }, 
            {
                "measure": "Part II - Change from Baseline in Peak Heart Rate at Day 14", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Day 14"
            }, 
            {
                "measure": "Part II - Change from Baseline in Peak Heart Rate at Day 19", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Day 19"
            }, 
            {
                "measure": "Part II - Change from Baseline in Peak Heart Rate at Day 24", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Day 24"
            }, 
            {
                "measure": "Part II - Change from Baseline in Peak Heart Rate at Day 29", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Day 29"
            }, 
            {
                "measure": "Part II - Change from Baseline in Resting Morning Heart Rate at Day 7", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Day 7"
            }, 
            {
                "measure": "Part II - Change from Baseline in Resting Morning Heart Rate at Day 14", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Day 14"
            }, 
            {
                "measure": "Part II - Change from Baseline in Resting Morning Heart Rate at Day 19", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Day 19"
            }, 
            {
                "measure": "Part II - Change from Baseline in Resting Morning Heart Rate at Day 24", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Day 24"
            }, 
            {
                "measure": "Part II - Change from Baseline in Resting Morning Heart Rate at Day 29", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Day 29"
            }, 
            {
                "measure": "Part II - AUC0-24 for MK-8521 Daily Dosing", 
                "safety_issue": "No", 
                "time_frame": "Days 7 (predose, 1, 2, 4, 6, 8, 10, 12, 16, and 24 hours post-dose); Day 14 (predose,1, 2, 4, 6, 8, 10, 12, 16, and 24 hours post-dose)"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01982630"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Part I - Change from Baseline for Fasting Plasma Glucose at Day 7 (FPG)", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Day 7"
            }, 
            {
                "measure": "Part I - Change from Baseline for FPG at Day 14", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Day 14"
            }, 
            {
                "measure": "Part I - Change from Baseline for 24-hour Weighted Mean Glucose (WMG) at Day 7", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Day 7"
            }, 
            {
                "measure": "Part I - Change from Baseline for 24-hour WMG at Day 14", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Day 14"
            }, 
            {
                "measure": "Part II - Change from Baseline for FPG at Day 7", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Day 7"
            }, 
            {
                "measure": "Part II - Change from Baseline for FPG at Day 14", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Day 14"
            }, 
            {
                "measure": "Part II - Change from Baseline for FPG at Day 19", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Day 19"
            }, 
            {
                "measure": "Part II - Change from Baseline for FPG at Day 24", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Day 24"
            }, 
            {
                "measure": "Part II - Change from Baseline for FPG at Day 29", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Day 29"
            }, 
            {
                "measure": "Part II - Change from Baseline for 24-hour WMG at Day 7", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Day 7"
            }, 
            {
                "measure": "Part II - Change from Baseline for 24-hour WMG at Day 14", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Day 14"
            }, 
            {
                "measure": "Part II - Change from Baseline for 24-hour WMG at Day 19", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Day 19"
            }, 
            {
                "measure": "Part II - Change from Baseline for 24-hour WMG at Day 24", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Day 24"
            }, 
            {
                "measure": "Part II - Change from Baseline for 24-hour WMG at Day 29", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Day 29"
            }
        ], 
        "source": "Merck Sharp & Dohme Corp.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}